Robin/openwiki-wiki
1
0
Fork 0
Code Issues Pull Requests Actions Packages Projects Releases Wiki Activity

chore: daily update 2026-07-30

Browse Source
This commit is contained in:
OpenWiki Bot
2026-07-30 02:13:32 +08:00
parent 61b7c0858b
commit e7d4f64e85
7 changed files with 173 additions and 31 deletions
Download Patch File Download Diff File Expand all files Collapse all files
.last-update.json
+1 -1
View File
@@ -1,5 +1,5 @@
{ {
"updatedAt": "2026-07-28T18:10:15.764Z", "updatedAt": "2026-07-29T18:13:32.946Z",
"command": "update", "command": "update",
"model": "MiniMax-M3" "model": "MiniMax-M3"
} }
commitments.md
+14
View File
@@ -25,6 +25,20 @@ Concrete work tasks, follow-ups, approvals, and scheduled items extracted from G
- Status: open - Status: open
- Notes: Single primary source (BetaLife SG LinkedIn) but the regulation itself is a published policy text — Order No. 818 creates an accelerated clinical-translation pathway at qualified hospitals for cell therapy and 3D bioprinting after demonstrating safety and preliminary efficacy. This is **the clinical-translation counterpart** to the existing `china-cde-cell-gene-therapy-rules-2026` item (which is about classification / CMC planning). Both items matter: classification scope drives dossier content vendors need to assemble; the clinical-translation pathway drives which hospitals can host first-in-human studies. Pull the NMPA / State Council Order No. 818 direct text before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deal depends on whether the buyer hospital qualifies as a "qualified hospital" under the regulation. - Notes: Single primary source (BetaLife SG LinkedIn) but the regulation itself is a published policy text — Order No. 818 creates an accelerated clinical-translation pathway at qualified hospitals for cell therapy and 3D bioprinting after demonstrating safety and preliminary efficacy. This is **the clinical-translation counterpart** to the existing `china-cde-cell-gene-therapy-rules-2026` item (which is about classification / CMC planning). Both items matter: classification scope drives dossier content vendors need to assemble; the clinical-translation pathway drives which hospitals can host first-in-human studies. Pull the NMPA / State Council Order No. 818 direct text before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deal depends on whether the buyer hospital qualifies as a "qualified hospital" under the regulation.
### cellink-bio-x-gen3-customer-evidence: verify Cellink BIO X Gen 3 / BIO X6 customer pipeline on next Cellink check
- Owner: me
- Source: web-search — Nuclear Mechano-Oncology LinkedIn 2026-07 (score 0.601; "our new BIO X Gen 3 bioprinter has now been installed … first hands-on training session"); CELLINK official LinkedIn 2026-07-28 (score 0.287; BIO X6 at University of Miami 3D Bioprinting Facility); third-party market report LinkedIn 2026-07-28 (score 0.659; Cellink revenue uptick following strategic acquisitions); appellaser.ro practical selection guide 2026-07-24 (score 0.303; BIO X Gen 3 general-purpose positioning)
- Due: unscheduled
- Status: open
- Notes: First vendor-anchored Cellink signal in any Tavily pull after 5 prior pulls of zero Cellink product mentions. Four distinct sources: customer install LinkedIn (Eastern Europe), vendor LinkedIn (CELLINK U. Miami), market report, independent selection guide. Verify with Cellink whether the BIO X Gen 3 / BIO X6 nomenclature is current product naming or if one is being deprecated; whether any of the named customer accounts (Nuclear Mechano-Oncology; U. Miami 3D Bioprinting Facility) maps to active Chinese pharma R&D / CDMO opportunities. Companion to the existing `celvivo-clinoreactor-thewell-bioscience-xeno-free` item.
### china-cgt-2026-july-developments: monitor gene-editing trial death fallout + Merck–Bio-Techne / CARsgen satri-cel context for Chinese pharma / CDMO positioning
- Owner: me
- Source: web-search — Straits Times 2026-07-24 (score 0.313; patient death in China gene-editing trial draws fire); LiveScience 2026-07-24 (score 0.145; 6-year-old girl, investigation into gene-therapy regulations); SCMP 2026-07-29 (score 0.203; "Fear of policy backlash" — same-day coverage with this Tavily pull); Roots Analysis 2026-07-24 (score 0.669; Merck–Bio-Techne $11.3B acquisition June 2026 + CARsgen satri-cel CAR-T approval for stomach cancer June 2026); BioSpace 2026-07-27 (score 0.535; Summit/Merck China-first regulatory navigation)
- Due: unscheduled
- Status: open
- Notes: Material new development in the China regulatory lane — sits **on top of** the existing `china-cde-cell-gene-therapy-rules-2026` and `china-order-no-818-clinical-translation` items, not replacing them. Two positive signals (Merck–Bio-Techne acquisition; CARsgen satri-cel solid-tumor CAR-T approval) show the China CGT manufacturing environment is consolidating around advanced therapeutics. One negative signal (gene-editing trial death + published regulatory backlash) could foreshadow stricter CDE / NMPA / hospital-level oversight and tighter qualification criteria for "qualified hospitals" under Order No. 818. Together these affect: (a) qualification timelines for the CellShot-TriArm and ClinoReactor-class deals Robin has in flight, (b) which "qualified hospitals" remain eligible to host first-in-human studies, (c) whether CelVivo / 3Brain / Cellink vendor positioning for Chinese pharma R&D / CDMO accounts needs to change tone (e.g. emphasize safety documentation, IRB-grade workflows). Pull NMPA / hospital-IRB statements on the gene-editing trial case before next Chinese customer conversation.
<!-- <!--
Structure for new entries: Structure for new entries:
quickstart.md
+4 -4
View File
@@ -23,7 +23,7 @@
- **Wiki state:** initialized — Hacker News, the local Obsidian vault, and Tavily web search are active and feeding `/sources/hackernews.md`, `/sources/git-repo.md`, `/sources/web-search.md`, and `/themes.md`. - **Wiki state:** initialized — Hacker News, the local Obsidian vault, and Tavily web search are active and feeding `/sources/hackernews.md`, `/sources/git-repo.md`, `/sources/web-search.md`, and `/themes.md`.
- **Connectors:** Hacker News, git-repo, and web search active. Gmail, Slack, Notion, and X are not yet configured — see "Adding sources" below. - **Connectors:** Hacker News, git-repo, and web search active. Gmail, Slack, Notion, and X are not yet configured — see "Adding sources" below.
- **Last update:** see [/.last-update.json](/.last-update.json) — this run was a `git-repo` refresh (`obsidian-robin-1` pulled 2026-07-28 18:07 UTC). The Obsidian vault HEAD advanced from `62877d1f` (2026-07-22) to `21491578` (2026-07-28), with **4 new commits on `main`** (all dated 2026-07-28): Hodge 2025 RegenMed Bio-Block MSC 4-week comparison, Lee 2025 Front Vet Sci canine MSC 3D spheroid (Wiki.js + NocoDB-linked), Parate 2020 PEMF MSC paracrine cartilage, and a new CelVivo distributor technical-contact profile (`02-Clients/Agents/董慧群.md`) — the latter is the first entry in the new `02-Clients/Agents/` bucket and most fields (agency, region, contact, served customers) are still 待补. The 5 untracked files from the prior pull (Raji 2026, Tasevska 2025, Bosnjakovic 2025, PressNet 2026-07-07, OpenWiki cheat sheet) carry over unchanged; the `skills/openclaw-workspace` submodule now reports a `-dirty` suffix (hash unchanged, no content delta). All four new commits are inside the 7-day "vault fresh" window so no `commitments.md` "vault fresh" row fires. The 董慧群 profile's open fields are logged as a new Active entry on `/open-questions.md` (`agent-dong-huiqun-celvivo`) so future agents can reason about CelVivo-channel activity once Robin fills them in. Detailed manifest + structural index in `/sources/git-repo.md`. - **Last update:** see [/.last-update.json](/.last-update.json) — this run was a `git-repo` vault-fresh refresh (`obsidian-robin-1` pulled 2026-07-29 18:07 UTC). HEAD advanced from `21491578` → `1a81e485` (+2 commits dated 2026-07-29: `81671c69` feat Organoids 2026 综述 deep-read + `1a81e485` SOP-rewrite of the same file — both land in `04-Literature/Deep-Reads/Organoid/`). No new themes, commitments, or open-questions rows; HN + web-search lanes were unchanged from the prior pull so `/sources/hackernews.md` and `/sources/web-search.md` carry over without edit. Previous material-evidence run (web-search refresh `web-search-1` pulled 2026-07-29 18:03 UTC) — Three lanes produced material new evidence: (a) **first vendor-anchored Cellink BIO X Gen 3 / BIO X6 signal** (Nuclear Mechano-Oncology install LinkedIn, CELLINK official LinkedIn promoting BIO X6 at U. Miami, third-party market report noting Cellink revenue uptick, appellaser selection guide) — promoted to `/commitments.md` as `cellink-bio-x-gen3-customer-evidence`; (b) **China CGT regulatory landscape material updates** (Roots Analysis: Merck–Bio-Techne $11.3B June 2026 + CARsgen satri-cel CAR-T solid-tumor approval June 2026; SCMP/LiveScience/Straits Times: gene-editing trial death in 6-year-old + published regulatory backlash 2026-07-24 → 2026-07-29) — promoted to `/commitments.md` as `china-cgt-2026-july-developments`; (c) **Hermes Agent v0.19 docs continue** (NousResearch/hermes-agent `configuration.md` 2026-07-26 documents iteration-budget behavior change; `features/api-server.md` 2026-07-27 documents new `/v1/runs/{run_id}/stop` + `/approval` endpoints with MiniMax-M3 as the documented default) — refreshes `hermes-agent-v0-19-quicksilver` Last seen → 2026-07-29. Also: `agent-memory-architecture` cluster grows to 12+ distinct sources (Hackernoon Moorcheh.ai "Agent Memory Has a Lock-In Problem. Open Formats Are How We Fix It." is the strongest OpenWiki-aligning source yet — pull-request review of agent memory); `MiniMax-m3` refresh (MyClaw.ai 2026-07-29 confirms M3 + M2.7 as operational models for both OpenClaw and Hermes); `class-organoid-3d-bioprinting` refresh (GEN "Large Bioprinted Tissues Get a Precision Boost" 2026-07-29; MDPI Cells volumetric bioprinting + hepatic organoid 2026-07-27; CN Bio + Ligand Pharmaceuticals + Sequel Med Tech deal; NASA AVATAR with Emulate OOC). Tavily answer-text mis-attribution persists on Q2 3Brain (5th pull in a row) — flagged in `/sources/web-search.md`. Detailed evidence on `/sources/web-search.md` pull 6.
## How to use this wiki ## How to use this wiki
@@ -53,9 +53,9 @@ Deferred until Robin configures connectors or asks for specific documentation:
- **Slack evidence index** — `/sources/slack.md` (no Slack connector configured yet) - **Slack evidence index** — `/sources/slack.md` (no Slack connector configured yet)
- **Notion evidence index** — `/sources/notion.md` (no Notion MCP configured yet) - **Notion evidence index** — `/sources/notion.md` (no Notion MCP configured yet)
- **X / Twitter evidence index** — `/sources/x.md` (no X connector configured yet) - **X / Twitter evidence index** — `/sources/x.md` (no X connector configured yet)
- **Hacker News evidence index** — `/sources/hackernews.md` (active; last refreshed 2026-07-28 18:00 UTC) - **Hacker News evidence index** — `/sources/hackernews.md` (active; last refreshed 2026-07-29 18:00 UTC)
- **Web search evidence index** — `/sources/web-search.md` (active; last refreshed 2026-07-28 18:04 UTC) - **Web search evidence index** — `/sources/web-search.md` (active; last refreshed 2026-07-29 18:03 UTC)
- **Git repo evidence index** — `/sources/git-repo.md` (active; last refreshed 2026-07-28 18:07 UTC — covers Robin's Obsidian vault) - **Git repo evidence index** — `/sources/git-repo.md` (active; last refreshed 2026-07-29 18:07 UTC — covers Robin's Obsidian vault)
- **Project / people / company pages** — only created when durable entities emerge from ingested data - **Project / people / company pages** — only created when durable entities emerge from ingested data
These are intentionally blank until there is real evidence to put in them. Populating them with placeholders would dilute the synthesis layer. These are intentionally blank until there is real evidence to put in them. Populating them with placeholders would dilute the synthesis layer.
sources/git-repo.md
+37 -19
View File
@@ -11,14 +11,17 @@ the vault, not summarize their content.
- **Instance:** `obsidian-robin` (source id `obsidian-robin-1`) - **Instance:** `obsidian-robin` (source id `obsidian-robin-1`)
- **Repo path:** `/mnt/c/Users/20864/.openclaw/workspace` - **Repo path:** `/mnt/c/Users/20864/.openclaw/workspace`
- **Branch:** `main` - **Branch:** `main`
- **HEAD:** `21491578ec22733f15efda864e88e44823171e6a` (2026-07-28) - **HEAD:** `1a81e485b6f8a4496122464f1151702d09f03cf0` (2026-07-29)
- **Ahead of origin/main:** 7 commits (3 CellShot-TriArm-Demo plans + 4 new commits - **Ahead of origin/main:** 9 commits (3 CellShot-TriArm-Demo plans + 4 dated
dated 2026-07-28: Hodge 2025 / Lee 2025 / Parate 2020 deep reads + 董慧群 2026-07-28: Hodge 2025 / Lee 2025 / Parate 2020 deep reads + 董慧群
CelVivo distributor technical-contact profile, un-pushed as of this run). CelVivo distributor technical-contact profile + 2 dated 2026-07-29:
`81671c69` Organoids 2026 综述 feat deep-read + `1a81e485` SOP-rewrite
pass on the same file — un-pushed as of this run).
- **Auth:** local path only — no remote, no credentials - **Auth:** local path only — no remote, no credentials
- **Latest fetch:** `2026-07-28T18:07:57Z` (HEAD advanced from `62877d1f` → `21491578`, - **Latest fetch:** `2026-07-29T18:07:33Z` (HEAD advanced from `21491578` →
+4 commits; untracked working-tree list unchanged from the prior pull) `1a81e485`, +2 commits; untracked working-tree list unchanged from the
- **Raw manifest:** `~/.openwiki/connectors/git-repo/raw/2026-07-28T18-07-57-114Z/manifest.json` prior pull — same 5 carryover files + submodule `-dirty` suffix)
- **Raw manifest:** `~/.openwiki/connectors/git-repo/raw/2026-07-29T18-07-33-803Z/manifest.json`
- **Source config:** `~/.openwiki/connectors/git-repo/config.json` - **Source config:** `~/.openwiki/connectors/git-repo/config.json`
## Working-tree status ## Working-tree status
@@ -49,17 +52,20 @@ the vault, not summarize their content.
cheat sheet ("一天 6 次对话的完整沉淀"). Date stamp 2026-07-27. cheat sheet ("一天 6 次对话的完整沉淀"). Date stamp 2026-07-27.
*(carryover from prior pull)* *(carryover from prior pull)*
Since the prior fetch (2026-07-27T18:07:54Z), **4 new commits have landed on Since the prior fetch (2026-07-28T18:07:57Z), **2 new commits have landed on
`main`** — HEAD advanced from `62877d1f` (2026-07-22) to `21491578` `main`** — HEAD advanced from `21491578` (2026-07-28) to `1a81e485`
(2026-07-28). All four are dated 2026-07-28 and are well inside the 7-day (2026-07-29). Both are dated 2026-07-29 and are well inside the 7-day
"vault fresh" window, so the staleness rule does not fire. Working-tree "vault fresh" window, so the staleness rule does not fire. Working-tree
deltas this run: the `skills/openclaw-workspace` submodule `-dirty` suffix deltas this run: the `skills/openclaw-workspace` submodule `-dirty` suffix
(unchanged commit hash; no content delta) plus the same 5 untracked files (unchanged commit hash; no content delta) plus the same 5 untracked files
the prior pull already recorded. The three new 2026-07-28 vendor-paper the prior pull already recorded. The two new 2026-07-29 commits are a
deep reads landed as **committed** files this pull, not as untracked working paired add+rewrite (`81671c69` feat deep-read of "Organoids for disease
files — they appear in the Recent commits table below, not above. modeling and treatment 2026 综述" PMID 41545895 / PMC12828948 into
Companion deep-read pages already exist for the three carryover vendor-paper `04-Literature/Deep-Reads/Organoid/`, then `1a81e485` fix pass to rewrite
notes: `/sources/literature-raji-2026-deepread.md`, the same file using the `literature-deep-read-review` SOP — 按主题分块 +
三段式 + 落款). The Organoid/ bucket is now +1 since this run lands
one new committed file. Companion deep-read pages already exist for the
three carryover vendor-paper notes: `/sources/literature-raji-2026-deepread.md`,
`/sources/literature-tasevska-2025-deepread.md`, and `/sources/literature-tasevska-2025-deepread.md`, and
`/sources/literature-cel-bosnjakovic-2025-pah-deepread.md`. `/sources/literature-cel-bosnjakovic-2025-pah-deepread.md`.
@@ -94,7 +100,7 @@ Markdown file counts per deep-read subfolder:
| Subfolder | .md count | | Subfolder | .md count |
| --- | --- | | --- | --- |
| `Organoid/` | 658 | | `Organoid/` | 659 |
| `Celvivo/` | 142 | | `Celvivo/` | 142 |
| `3Brain/` | 136 | | `3Brain/` | 136 |
| `Cellink/` | 129 | | `Cellink/` | 129 |
@@ -111,11 +117,13 @@ Markdown file counts per deep-read subfolder:
| `Kidney/` | 2 | | `Kidney/` | 2 |
| `Retinal/` | 1 | | `Retinal/` | 1 |
Total ≈ 1,201 deep-read notes (+3 committed 2026-07-28 vendor/adjacent Total ≈ 1,202 deep-read notes (+3 committed 2026-07-28 vendor/adjacent
deep-reads since the prior pull: +2 `Other/` — Lee 2025 Front Vet Sci deep-reads since the pull before that: +2 `Other/` — Lee 2025 Front Vet Sci
canine MSC 3D spheroid + Parate 2020 SCRT PEMF MSC paracrine cartilage; canine MSC 3D spheroid + Parate 2020 SCRT PEMF MSC paracrine cartilage;
+1 new `RegenMed/` bucket — Hodge 2025 Bio-Block MSC 4-week comparison; +1 new `RegenMed/` bucket — Hodge 2025 Bio-Block MSC 4-week comparison;
the Organoid/ bucket is unchanged since none of the new files land there). the Organoid/ bucket is now +1 from this run's two new commits
(`81671c69` Organoids 2026 综述 feat deep-read + `1a81e485` SOP-rewrite
of the same file) — neither `Other/` nor `RegenMed/` changed this run).
CelVivo, 3Brain, Cellink, and the broad `Organoid/` bucket cover Robin's CelVivo, 3Brain, Cellink, and the broad `Organoid/` bucket cover Robin's
product KB per the wiki goal focus areas (类器官培养与设备, 3D 生物打印). product KB per the wiki goal focus areas (类器官培养与设备, 3D 生物打印).
The new `RegenMed/` bucket is application-domain adjacent (Bio-Block vs. The new `RegenMed/` bucket is application-domain adjacent (Bio-Block vs.
@@ -129,6 +137,8 @@ Pulled from the manifest's `recentCommits` field. Date stamps via
| Date | Hash | Note | | Date | Hash | Note |
| --- | --- | --- | | --- | --- | --- |
| 2026-07-29 | 1a81e485 | fix(literature): Organoids 2026 综述 - 按 literature-deep-read-review SOP 重写 (按主题分块 + 三段式 + 落款) |
| 2026-07-29 | 81671c69 | feat(literature): 精读 Organoids for disease modeling and treatment 2026 综述 (PMID 41545895, PMC12828948) |
| 2026-07-28 | 21491578 | feat(agent): 新增代理商技术同事董慧群档案 (推 CelVivo 产品) | | 2026-07-28 | 21491578 | feat(agent): 新增代理商技术同事董慧群档案 (推 CelVivo 产品) |
| 2026-07-28 | 652e0e60 | feat(literature): Parate 2020 SCRT — PEMF 增强 MSC 旁分泌功能促软骨再生 (中文精读, 10 图 + 4 功能) | | 2026-07-28 | 652e0e60 | feat(literature): Parate 2020 SCRT — PEMF 增强 MSC 旁分泌功能促软骨再生 (中文精读, 10 图 + 4 功能) |
| 2026-07-28 | ee34cf83 | feat: 精读 Lee 2025 Front Vet Sci 犬脂肪源 MSC 3D 球体（Wiki.js Id=1645, NocoDB Id=3290） | | 2026-07-28 | ee34cf83 | feat: 精读 Lee 2025 Front Vet Sci 犬脂肪源 MSC 3D 球体（Wiki.js Id=1645, NocoDB Id=3290） |
@@ -189,6 +199,14 @@ in the `git status` dirty tree):
| `04-Literature/Deep-Reads/Other/2026-07-28_Lee_2025_FrontVetSci_canine_MSC_3D_spheroid.md` | added (commit `ee34cf83`) | Lee 2025 Front Vet Sci — 犬脂肪源MSC 3D球体 (Wiki.js Id=1645, NocoDB Id=3290) | | `04-Literature/Deep-Reads/Other/2026-07-28_Lee_2025_FrontVetSci_canine_MSC_3D_spheroid.md` | added (commit `ee34cf83`) | Lee 2025 Front Vet Sci — 犬脂肪源MSC 3D球体 (Wiki.js Id=1645, NocoDB Id=3290) |
| `04-Literature/Deep-Reads/RegenMed/2026-07-28_Hodge_2025_RegenMed_MSC_3D_Bio-Block.md` | added (commit `5ddda558`) | Hodge 2025 RegenMed — Bio-Block 4周MSC长期培养对比 (Wiki.js + SeaFile 7图 PDF) | | `04-Literature/Deep-Reads/RegenMed/2026-07-28_Hodge_2025_RegenMed_MSC_3D_Bio-Block.md` | added (commit `5ddda558`) | Hodge 2025 RegenMed — Bio-Block 4周MSC长期培养对比 (Wiki.js + SeaFile 7图 PDF) |
The 2 commits added on 2026-07-29 brought this file into `main` (visible
in `git log` and the manifest's `recentCommits` field, not in the
`git status` dirty tree):
| Path | Change | Note |
| --- | --- | --- |
| `04-Literature/Deep-Reads/Organoid/2026-07-29_Organoids_disease_modeling_treatment_2026_review.md` | added (commit `81671c69`) then modified (commit `1a81e485`) | Organoids for disease modeling and treatment 2026 综述 (PMID 41545895, PMC12828948); commit `1a81e485` is the SOP-rewrite pass (按主题分块 + 三段式 + 落款) |
## Notable entities surfaced by the vault (structural hints only) ## Notable entities surfaced by the vault (structural hints only)
- **CelVivo industrial customers program** — a dedicated subfolder under - **CelVivo industrial customers program** — a dedicated subfolder under
sources/hackernews.md
+19 -3
View File
@@ -8,10 +8,26 @@ Compact evidence trail for the Hacker News connector (`hackernews-1`, Robin-cura
- **Backend:** public HN feeds (`top`, `new`) + Algolia HN search queries - **Backend:** public HN feeds (`top`, `new`) + Algolia HN search queries
- **Auth:** none — public feeds - **Auth:** none — public feeds
- **Window:** last 24 hours - **Window:** last 24 hours
- **Latest fetch:** `2026-07-28T18:00:42Z` (latest 18:00 pull on 2026-07-28; prior 2026-07-27 18:00, 2026-07-26 18:16 and 18:00 pulls also documented below) - **Latest fetch:** `2026-07-29T18:00:02Z` (latest 18:00 pull on 2026-07-29; prior 2026-07-28 18:00, 2026-07-27 18:00, 2026-07-26 18:16 and 18:00 pulls also documented below)
- **Raw dumps:** `~/.openwiki/connectors/hackernews/raw/2026-07-28T18-00-02-178Z/hackernews-results.json` (current) · `~/.openwiki/connectors/hackernews/raw/2026-07-27T18-00-02-615Z/hackernews-results.json` · `~/.openwiki/connectors/hackernews/raw/2026-07-26T18-16-06-805Z/hackernews-results.json` · `~/.openwiki/connectors/hackernews/raw/2026-07-26T18-00-02-441Z/hackernews-results.json` - **Raw dumps:** `~/.openwiki/connectors/hackernews/raw/2026-07-29T18-00-02-667Z/hackernews-results.json` (current) · `~/.openwiki/connectors/hackernews/raw/2026-07-28T18-00-02-178Z/hackernews-results.json` · `~/.openwiki/connectors/hackernews/raw/2026-07-27T18-00-02-615Z/hackernews-results.json` · `~/.openwiki/connectors/hackernews/raw/2026-07-26T18-16-06-805Z/hackernews-results.json` · `~/.openwiki/connectors/hackernews/raw/2026-07-26T18-00-02-441Z/hackernews-results.json`
## Latest update — 2026-07-28 18:00 UTC ## Latest update — 2026-07-29 18:00 UTC
- **Coverage:** 2 feeds (`top`, `new`), 24 search queries (the same life-science + workflow set the 2026-07-28 18:00 pull used), 27 + 30 = 57 unique resolved feed stories, and the life-science / vendor / workflow lane hit table below.
- **Life-science lane:** **zero search-query hits** across all 14 life-science / vendor queries — `organoid`, `3D bioprinting`, `3D bioprinter`, `bioprinting clinical`, `spheroid bioreactor`, `microgravity cell culture`, `CELVIVO`, `3Brain`, `Cellink`, `MEA neuroscience`, `organ-on-chip`, `liver organoid`, `brain organoid`, `spheroid drug screening` all returned no results. A title/url regex sweep across the top + new feeds also turned up zero organoid / 3D-bioprinting / CelVivo / 3Brain / Cellink / ClinoStar / ClinoReactor / MEA / spheroid / organ-on-chip items. The prior "no material HN footprint for the 4 vendor lines" finding still holds.
- **Workflow lane:** **zero search-query hits** across all 10 workflow queries — `OpenWiki`, `OpenWiki personal brain`, `Hermes Agent`, `Claude Code agent workflow`, `Codex CLI`, `RAGFlow`, `agent memory wiki`, `agent personal brain`, `MCP connector agent`, `MiniMax` all returned no results. The feed sweep caught the recurring Kimi/K3 cluster (item `49098130` "Self-hosting Kimi K3: 20% more hardware cost, 20% better task resolution", 51 pts) — off-scope per brief (open-weight AI never earns a themes.md row).
- **High-engagement top-feed items not promoted:** `49098510` "Show HN: Open-source engine running Gemma 4 26B in 2 GB RAM on any M-series Mac" (317 pts) — local-LLM / hardware signal, off-scope; `49096188` "Document-borne AI worms can self-propagate through Copilot for Word" (249 pts) — security, off-scope; `49096969` "Handbook.md shows that long policy documents do not reliably govern agents" (207 pts) — adjacent to the existing `agent-memory-architecture` watchlist (a generic empirical result about agents and long policy docs), but not a direct change to Hermes / MiniMax / OpenWiki / RAGFlow / NocoDB / SeaFile, so it stays on the adjacent-not-promoted list rather than earning a themes.md row per the brief's "Workflow tooling (priority LOW) — surface story-worthy changes only" rule; `49098466` "Hugging Face: Anatomy of a frontier-lab agent intrusion" (87 pts) — security, off-scope; `49098198` "A.I. companies are recruiting electricians and carpenters by the thousands" (63 pts) — labor market, off-scope; `49098388` "GPT-5.6 vs. Claude Fable 5 for Physical AI" (41 pts) — model comparison, off-scope; `49099143` "Launch HN: Tokenless (YC S26) – Automatic model switching to save money" (32 pts) — generic YC launch, off-scope; `49098260` "Show HN: Qwen Scribe – local transcription and dictation for Apple Silicon" (27 pts) — local inference, off-scope; `49100035` "Infrastructure Patterns for Agentic Applications" (23 pts) — generic agent infra, off-scope; `49097908` "CipherX applies painless permanent tattoos with dissolving microneedle patches" (17 pts) — microneedle patches adjacent to bioprinting but the application is cosmetic tattooing, not 3D bioprinting, so off-scope per brief.
- **New-feed items not promoted:** all 30 items were either 1–6 pts, off-scope news (Walmart EV charging, Next.js .next folder cleanup, Spiderman, Edible ants, Federal employees, etc.), or already off-scope clusters (rogue agent security at `49100529`, AI rental faces in China at `49100598`, AI on lost languages at `49100590`, the `49100656` "Give every AI project its own computer" generic agent post). None matches a Robin in-scope keyword.
- **Synthesis result:** **no theme refresh, no commitment row, no open-question row.** `class-organoid-3d-bioprinting` last-seen stays at 2026-07-28 (item `49083799` from the prior pull — this 24h window is empty of organoid signal). The Kimi/K3 cluster continues to dominate the workflow lane at moderate engagement but stays off-scope per the brief.
| Query lane | Queries run | Qualifying results |
| --- | --- | --- |
| Life sciences / vendors | `organoid`, `3D bioprinting`, `3D bioprinter`, `bioprinting clinical`, `spheroid bioreactor`, `microgravity cell culture`, `CELVIVO`, `3Brain`, `Cellink`, `MEA neuroscience`, `organ-on-chip`, `liver organoid`, `brain organoid`, `spheroid drug screening` | 0 |
| AI workflow | `OpenWiki`, `OpenWiki personal brain`, `Hermes Agent`, `Claude Code agent workflow`, `Codex CLI`, `RAGFlow`, `agent memory wiki`, `agent personal brain`, `MCP connector agent`, `MiniMax` | 0 |
Raw dump: `~/.openwiki/connectors/hackernews/raw/2026-07-29T18-00-02-667Z/hackernews-results.json`.
## Update — 2026-07-28 18:00 UTC
- **Coverage:** 2 feeds (`top`, `new`), 24 search queries (the same life-science + workflow set the 2026-07-27 18:00 pull used), 58 unique resolved feed stories, and the life-science / vendor / workflow lane hit table below. - **Coverage:** 2 feeds (`top`, `new`), 24 search queries (the same life-science + workflow set the 2026-07-27 18:00 pull used), 58 unique resolved feed stories, and the life-science / vendor / workflow lane hit table below.
- **Life-science lane:** `organoid` returned 6 hits — one genuinely relevant (`49083799`, owlposting drug-discovery essay, 9 pts — see `class-organoid-3d-bioprinting (refreshed this run)` below); the rest were string collisions (Countify no-code computer vision, Shoebox Plus, "Bonfire" communities, anti-fraud, plus the YC S26 Rise Reforming launch also caught by the `Cellink` query). `3Brain` returned 8 hits (all string collisions: aeon bioenergetics essay, SpiNNaker2 chip, "local-first second brain" repo, "Use Your Brain" engineering blog, "Rachel has a new brain" reddit post, "Brain waves as noise" essay). `Cellink` returned 3 hits (Nutaan voice assistant, Rise Reforming — same as `organoid`, and a Kimi-K3 downloader). `liver organoid` and `brain organoid` each returned 1 hit — both string collisions (Shoebox Plus, Countify). `CELVIVO`, `3D bioprinting`, `3D bioprinter`, `bioprinting clinical`, `spheroid bioreactor`, `microgravity cell culture`, `MEA neuroscience`, `organ-on-chip`, `spheroid drug screening` all returned `nbHits=0` — the prior pulls' "no material HN footprint for the 4 vendor lines" finding still holds. - **Life-science lane:** `organoid` returned 6 hits — one genuinely relevant (`49083799`, owlposting drug-discovery essay, 9 pts — see `class-organoid-3d-bioprinting (refreshed this run)` below); the rest were string collisions (Countify no-code computer vision, Shoebox Plus, "Bonfire" communities, anti-fraud, plus the YC S26 Rise Reforming launch also caught by the `Cellink` query). `3Brain` returned 8 hits (all string collisions: aeon bioenergetics essay, SpiNNaker2 chip, "local-first second brain" repo, "Use Your Brain" engineering blog, "Rachel has a new brain" reddit post, "Brain waves as noise" essay). `Cellink` returned 3 hits (Nutaan voice assistant, Rise Reforming — same as `organoid`, and a Kimi-K3 downloader). `liver organoid` and `brain organoid` each returned 1 hit — both string collisions (Shoebox Plus, Countify). `CELVIVO`, `3D bioprinting`, `3D bioprinter`, `bioprinting clinical`, `spheroid bioreactor`, `microgravity cell culture`, `MEA neuroscience`, `organ-on-chip`, `spheroid drug screening` all returned `nbHits=0` — the prior pulls' "no material HN footprint for the 4 vendor lines" finding still holds.
sources/web-search.md
+94
View File
@@ -225,3 +225,97 @@ The `agent personal memory wiki 2026` query returned five same-week sources on a
- **No new vendor-anchored evidence** on CelVivo, 3Brain, Cellink, CellShot/TriArm, or Hermes this pull. The prior vendor-anchored items (CelVivo+TheWell, Hermes v0.19 Quicksilver) remain on disk and referenceable; the Hermes row's Last seen is **not** refreshed because the underlying URLs in this pull returned Apple-product noise. - **No new vendor-anchored evidence** on CelVivo, 3Brain, Cellink, CellShot/TriArm, or Hermes this pull. The prior vendor-anchored items (CelVivo+TheWell, Hermes v0.19 Quicksilver) remain on disk and referenceable; the Hermes row's Last seen is **not** refreshed because the underlying URLs in this pull returned Apple-product noise.
- **Tavily answer-text mis-attribution pattern persists** on 3Brain (4th pull), Cellink (4th pull), and Hermes (1st pull). This is a Tavily-side quality issue; treat Tavily answer text as untrusted and only the underlying URLs as evidence. Continued recommendation: narrow future pulls to vendor-name-anchored queries only. - **Tavily answer-text mis-attribution pattern persists** on 3Brain (4th pull), Cellink (4th pull), and Hermes (1st pull). This is a Tavily-side quality issue; treat Tavily answer text as untrusted and only the underlying URLs as evidence. Continued recommendation: narrow future pulls to vendor-name-anchored queries only.
- **OpenWiki / RAGFlow / agent-memory lane behavior changed.** The lane still produces zero OpenWiki/RAGFlow/SeaFile/NocoDB/Gitea results, but the **agent-personal-memory-wiki** lane is now high-signal for the OKF/LLM Wiki architecture — strong enough to promote the existing `agent-memory-architecture` row. - **OpenWiki / RAGFlow / agent-memory lane behavior changed.** The lane still produces zero OpenWiki/RAGFlow/SeaFile/NocoDB/Gitea results, but the **agent-personal-memory-wiki** lane is now high-signal for the OKF/LLM Wiki architecture — strong enough to promote the existing `agent-memory-architecture` row.
---
## 2026-07-29 18:03 pull
Sixth Tavily pull, run as a stand-alone `openwiki personal --update` source ingest. All 10 queries re-run. Three lanes produced material new evidence: Cellink BIO X Gen 3 first-time vendor-anchored signal; China CGT regulatory landscape material updates (Merck–Bio-Techne, CARsgen satri-cel, gene-editing trial death + backlash); Hermes Agent v0.19 documentation continues (configuration.md, api-server.md). The CelVivo/TheWell xeno-free and China Order No. 818 items remain pinned in `/commitments.md`. The agent-memory-architecture cluster continues to grow. Tavily answer-text mis-attribution persists on Q2/Q3 (3Brain / Cellink) but the underlying URLs are now vendor-anchored for Cellink — a first.
### Cellink BIO X Gen 3 / BIO X6 — first vendor-anchored Cellink signal — source-backed
This is the **first vendor-anchored Cellink BIO X / BIO X6 / BIO X Gen 3 signal in any Tavily pull**. Prior pulls returned only MO:BOT, Roche, Cepheid, Velo3D, Cellares-Papillon, or generic bioprinting market reports — never Cellink product names in a vendor/customer context. Three same-week sources confirm Cellink product activity:
- **LinkedIn (Nuclear Mechano-Oncology), no exact date in 2026-07:** [BIO X Gen 3 Bioprinter Installed and Trained](https://www.linkedin.com/posts/nuclear-mechano-oncology_exciting-news-from-our-lab-our-new-bio-activity-7486350933371543552-CBoV). Score 0.601. A customer lab (Nuclear Mechano-Oncology) announces the install + first hands-on training of a BIO X Gen 3 bioprinter, with team members Ines Papak, Kamil Łangowski, Julia Jała named. Positions BIO X Gen 3 as "an important addition to our work on advanced 3D cell culture models and the development of more physiologically relevant cancer research platforms."
- **LinkedIn (CELLINK official channel), 2026-07-28:** [From Star Trek to the Clinic: 3D Bioprinting Facility is Engineering Molecules for Patient Implantation](https://www.linkedin.com/posts/cellink_from-star-trek-to-the-clinic-3d-bioprinting-activity-7487839428997046272-myqA). Score 0.287. CELLINK's own organization page (26,186 followers) highlights the University of Miami 3D Bioprinting Facility using CELLINK's BIO X6 in the toolkit for tissue engineering and patient-specific implants. Companion article from InventUM.
- **LinkedIn (Biomedical 3D Printer Market report), 2026-07-28:** [Biomedical 3D Printer Market Size and Growth at a 4.7% CAGR from 2026 to 2033](https://www.linkedin.com/pulse/biomedical-3d-printer-market-size-growth-47-bstsf). Score 0.659. Third-party market report explicitly names Cellink as a major player with "a significant uptick in their revenue stream" following "strategic acquisitions and increased market penetration" and notes Cellink's "focus on sustainable and customizable bioinks."
- **apellaser.ro, 2026-07-24:** [How to Choose a 3D Bioprinter: Practical Selection Guide](https://apellaser.ro/en/bioprinter-selection-guide). Score 0.303. Independent practical guide explicitly names "BIO X Gen 3 is the general-purpose choice for laboratories that need flexible extrusion and up to three interchangeable printheads or tools." Vendor-anchored reference, not a press release.
- **Tavily answer text** describes "The Cellink BIO X bioprinter, specifically the Gen 3 model, is a versatile tool for laboratories requiring flexible extrusion and up to three interchangeable printheads" — this time the answer text correctly identifies Cellink product naming (though it includes hallucinated "Gen 3" details in some phrases; the underlying URLs are the source of truth).
**Robin relevance:** HIGH. First vendor-anchored Cellink signal after 5 prior pulls of zero Cellink product mentions. The Nuclear Mechano-Oncology install is an Eastern European customer reference; the U. Miami BIO X6 mention is the same University of Miami 3D Bioprinting Facility that has been a recurring Cellink reference in industry press; the market report independently corroborates Cellink revenue growth. Promoted to `/commitments.md` as `cellink-bio-x-gen3-customer-evidence` for next-vendor-check verification (parallel structure to the CelVivo+TheWell row).
### China cell & gene therapy regulatory landscape — material updates — source-backed
The Q7 lane surfaced four distinct new items that materially update the existing `/commitments.md` `china-cde-cell-gene-therapy-rules-2026` and `china-order-no-818-clinical-translation` items. The gene-editing trial death + regulatory backlash is the most consequential — it directly affects how Robin positions 3Brain MEA + CelVivo ClinoReactor + Cellink BIO X for Chinese pharma R&D / CDMO / biotech customers.
- **Roots Analysis, 2026-07-24:** [Cell Therapy Manufacturing Market Size 2035](https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html). Score 0.669. Two new data points from the same Roots Analysis page: (a) **June 2026: Merck agreed to acquire Bio-Techne for ~$11.3B** to strengthen life-science capabilities across bioprocessing, advanced therapeutics, and integrated workflow solutions for cell-and-gene-therapy developers; (b) **June 2026: CARsgen Therapeutics received China NMPA approval for satri-cel, a CAR-T therapy for solid-tumor stomach cancer** — described as "an important milestone for solid tumor CAR-T therapies" expected to increase demand for specialized CAR-T manufacturing in Asia-Pacific.
- **BioSpace, 2026-07-27:** [Summit, Merck must navigate new regulatory terrain in China-first cancer landscape](https://www.biospace.com/drug-development/summit-merck-must-navigate-new-regulatory-terrain-in-china-first-cancer-landscape). Score 0.535. Frames the broader pattern of China-first cancer-drug development: Stifel analysts (2026-07-22 note) argue the HARMONi 2-year follow-up data is "a strong counter" to the "China data would not translate" bear argument. Implications for CDMO and instrument vendors supporting both Western and China-first pipelines.
- **Straits Times, 2026-07-24:** [Patient death in China gene-editing trial draws fire: Journal](https://www.straitstimes.com/asia/east-asia/patient-death-in-china-gene-editing-trial-draws-fire-journal). Score 0.313. A patient (later confirmed as a 6-year-old girl in follow-up coverage) died in an experimental gene-editing trial in China; the case is drawing published scrutiny of China's gene-therapy regulatory regime.
- **LiveScience, 2026-07-24:** [An experimental gene therapy killed a 6-year-old girl in China. Her parents are seeking accountability](https://www.livescience.com/health/genetics/6-year-old-in-china-dies-after-experimental-treatment-investigation-finds-raising-questions-about-the-countrys-gene-therapy-regulations). Score 0.145. Investigation-level coverage: raises "questions about the country's gene therapy regulations."
- **SCMP, 2026-07-29:** [Is China's biotech boom at risk? Fear of policy backlash after death in gene-editing trial](https://amp.scmp.com/news/china/science/article/3362253/chinas-biotech-boom-risk-fear-policy-backlash-after-death-gene-editing-trial). Score 0.203. Frames the same death as a potential inflection point for China's biotech regulatory regime — "Fear of policy backlash." Published same day as this Tavily pull, which is what surfaces it.
**Robin relevance:** HIGH (the gene-editing trial death item especially). The Merck–Bio-Techne acquisition and CARsgen satri-cel approval are positive indicators of the China CGT manufacturing environment. The gene-editing trial death + published regulatory scrutiny is the inverse signal: it could foreshadow stricter CDE / NMPA / hospital-level oversight, which would affect (a) qualification timelines for the CellShot-TriArm and ClinoReactor-class deals Robin has in flight, and (b) which "qualified hospitals" under Order No. 818 remain eligible. Promoted to `/commitments.md` as `china-cgt-2026-july-developments` to track this as a single follow-up item.
### Organ-on-chip pharma collaboration 2026 — source-backed (application-domain)
The Q4 lane returned two strong same-week items on organ-on-chip / pharma collaboration:
- **Business Weekly, 2026-07-24:** [Business Weekly Awards 2026: 44 shortlisted companies revealed for Cambridge Tech and Life Sciences showcase](https://www.businessweekly.co.uk/posts/business-weekly-awards-2026-44-shortlisted-companies-revealed-for-cambridge-tech-and-life). Score 0.754. **CN Bio** (Chesterford Research Park) shortlisted for the OOC PhysioMimix platform; profile explicitly cites a **$11m funding deal with Ligand Pharmaceuticals (Florida)** and a **co-development agreement with Sequel Med Tech LLC (New Hampshire)** as last-year's announcements.
- **SelectScience, 2026-07-28:** [Organ-Chips reach new frontiers with NASA's AVATAR project and next-gen preclinical testing](https://www.selectscience.net/article/organ-chips-reach-new-frontiers-with-avatar-and-next-gen-preclinical-testing). Score 0.736. NASA AVATAR (A Virtual Astronaut Tissue Analog Response) project uses OOC devices to study deep-space effects on human health; features Emulate's 96-chip AVA Emulation System helping pharma transition to human-relevant testing under FDA Modernization Act 2.0 / UK guidelines.
- **Nature, 2026-07-24:** [Engineering human Gut-on-a-Chip culturomics](https://www.nature.com/articles/s44385-026-00099-1) reappears at score 0.367 (re-mention from pulls 1 + 5).
**Robin relevance:** application-domain only — folds into the existing `class-organoid-3d-bioprinting` row. CN Bio / Emulate are not one of Robin's 4 vendor lines, but both are competitive/positioning signal for CelVivo-class bioreactors at pharma R&D accounts. NASA AVATAR is a high-visibility OOC application milestone.
### Hermes Agent v0.19 documentation refresh — source-backed (workflow tooling, low priority)
Q8 returned two NousResearch/hermes-agent repo documentation updates and one third-party M3-vs-OpenClaw comparison. The docs confirm v0.19+ work is still landing in the 2026-07-26 → 2026-07-29 window — same row as the v0.19 Quicksilver signal, more sources.
- **GitHub (NousResearch/hermes-agent `configuration.md`), 2026-07-26:** [Iteration Budget](https://github.com/NousResearch/hermes-agent/blob/main/website/docs/user-guide/configuration.md). Score 0.590. Documents the iteration-budget behavior change: "earlier builds warned the model at 70%/90% budget, which caused models to abandon complex tasks prematurely and was removed in April 2026." Now at default 500 turns, Hermes injects one wrap-up message at 500/500 with a single grace call. Story-worthy because it is a deliberate quality change, not just a number.
- **GitHub (NousResearch/hermes-agent `features/api-server.md`), 2026-07-27:** [POST /v1/runs/{run_id}/stop + /approval endpoints](https://github.com/NousResearch/hermes-agent/blob/main/website/docs/user-guide/features/api-server.md). Score 0.367. Documents the new `/v1/runs/{run_id}/stop` and `/v1/runs/{run_id}/approval` endpoints (returning `{"status": "stopping"}` and resolving approval policies). Sample JSON now uses `"model":"MiniMax-M3"` with provider `"minimax"` — M3 is the documented default.
- **MyClaw.ai, 2026-07-29:** [OpenClaw vs MiniMax Agent: Which AI Agent Should You Use in 2026?](https://myclaw.ai/blog/openclaw-vs-minimax-agent). Score 0.543. Third-party comparison: **OpenClaw supports MiniMax through OAuth with a Token Plan or API key.** M3 handles primary reasoning; M2.7 variants remain available. Multimodal (image, video, music, speech, web search) supported across M3 and M2.7.
- **Instagram (Sriram Varadharajan), no exact date in 2026-07:** [AI COMMAND CENTER TRIAL REEL — MiniMax M3 announcement](https://www.instagram.com/reel/DbVydtNj46Z). Score 0.497. Reels text references MiniMax M3 launch ("longer context, capability uplift over M2") and open-source readiness. Adjacent to MiniMax-M3 theme row.
**Robin relevance:** WORKFLOW TOOLING (low priority). The configuration.md change is a Hermes-side behavior update Robin's daily-driver stack benefits from; the api-server.md endpoints are runtime-control surfaces OpenWiki's MCP integration could exploit; MyClaw.ai confirms MiniMax M3 as the operational model for both OpenClaw and Hermes. Folded into the existing `hermes-agent-v0-19-quicksilver` and `MiniMax-m3` theme rows — refreshes Last seen but does not spawn a new row.
### Agent-memory-architecture cluster grows — source-backed (workflow tooling, low priority)
Q10 returned four new sources that further corroborate the existing `agent-memory-architecture` theme row. Combined with the prior 5 Tavily + 3 HN sources, the cluster now has 12+ distinct publishers converging on shared / open-format / persistent agent-memory architectures:
- **HPCwire, 2026-07-28:** [Exabase Reports State-of-the-Art Results on BEAM Memory Benchmark](https://www.hpcwire.com/aiwire/2026/07/28/exabase-reports-state-of-the-art-results-on-beam-memory-benchmark). Score 0.624. Exabase M-1 achieves highest reported score at every scale: **76.9% at 100K tokens, 75.0% at 1M tokens, 68.0% at 10M tokens**, using Gemini 3 Flash (a model "up to six times cheaper and faster" than Gemini 3 Pro used by every other leading system). 20% fewer tokens per query than next-best system.
- **Hackernoon (Moorcheh.ai CTO), 2026-07-28:** [Agent Memory Has a Lock-In Problem. Open Formats Are How We Fix It.](https://hackernoon.com/agent-memory-has-a-lock-in-problem-open-formats-are-how-we-fix-it). Score 0.605. Frames the lock-in problem explicitly: "Your agent has been in production for a year. … thousands of memories: user preferences, resolved decisions, corrections, domain facts. Now you want to move to a different memory system — better retrieval, better pricing, whatever. What's your migration path?" Argues for **Diffability** ("`git diff` shows exactly what your agent learned between two commits"), **Reviewability** ("Memory changes can go through pull requests like code"), and **Auditability** ("Regulated environment? Your …"). This is the most explicit OpenWiki-aligning post yet — pull-request review of agent memory is exactly what OpenWiki's synthesis workflow does.
- **Towards Data Science, 2026-07-24:** [Context Windows Forget What Matters — I Built a Usage-Reinforced Decay Engine for AI Agent Memory](https://towardsdatascience.com/context-windows-forget-what-matters-i-used-a-140-year-old-psychology-paper-to-fix-ai-memory). Score 0.576. Uses Ebbinghaus forgetting curve (1885) to design a spaced-repetition decay engine for agent memory. Cites the open-source **YourMemory** project (Mishra, 2026) as another Ebbinghaus-forgetting-curve implementation. Robin-relevant because OpenWiki's wiki synthesis itself is a form of spaced-repetition knowledge curation.
- **The Register, 2026-07-29:** [MinIO pitches persistent memory for agents with work to finish](https://www.theregister.com/storage/2026/07/29/minio-pitches-persistent-memory-for-agents-with-work-to-finish/5280407). Score 0.425. MinIO **AIStor Memory** for long-running multi-step agent workflows. Example use cases: software engineering agents across large codebases; deep research spanning hours or days; human-in-the-loop workflows that pause and resume; enterprise AI systems handling regulated data. The piece argues "agent-generated work accumulates, memory created for individual agents can become a shared organizational record built by humans and machines" — and that where that record lives is the architectural question OpenWiki sits at.
**Robin relevance:** WORKFLOW TOOLING (low priority). The cluster is now 12+ sources. The Hackernoon/Moorcheh.ai piece is the strongest single source for OpenWiki alignment (pull-request review of agent memory maps 1:1 onto OpenWiki's synthesis). The MinIO piece confirms enterprise infrastructure vendors are now treating "shared organizational memory built by humans and machines" as a product category. Refreshes `agent-memory-architecture` Last seen to 2026-07-29 and adds to evidence count.
### 3Brain / CellShot / installed-base / OpenWiki-RAGFlow / Tavily answer-text quality — same pattern
- **3Brain CorePlate MEA 2026:** Nature [portable semi-dry EEG device paper](https://www.nature.com/articles/s41598-026-52672-8) reappears at score 0.187 — **fifth pull in a row with the same mis-attribution**. Tavily answer text again labels it "3Brain CorePlate MEA 2026 … validated for its application in brain–computer interface solutions." Underlying paper is a portable EEG headset, not 3Brain MEA chips. Do not promote as 3Brain evidence.
- **Cellink BIO X bioprinter 2026:** as noted above, this pull is the first to return real Cellink product evidence. Tavily answer text was finally correct on the Cellink side this time ("Cellink BIO X bioprinter, specifically the Gen 3 model, is a versatile tool for laboratories requiring flexible extrusion and up to three interchangeable printheads").
- **CellShot / CellPick bioprinter 2026:** Tavily honestly says "The CellShot CellPick bioprinter 2026 is not mentioned in the provided data sources." Top hit is **GEN "Large Bioprinted Tissues Get a Precision Boost"** (2026-07-29 12:00:52 GMT, score 0.259) — application-domain news, no Femtobiomed vendor signal. The same GEN article reappears in Q1 (0.037), Q2 (0.032), and Q5 (0.259). Worth a note in `class-organoid-3d-bioprinting` evidence column.
- **labs CelVivo ClinoStar installed base 2026:** Tavily answer text returns a hallucinated claim: "As of today, July 29, 2026, the CelVivo ClinoStar is being installed in new A-Level (H2) science labs, such as the one opening in Eclat @ Henderson in August 2026." **No URL in the result set mentions CelVivo, ClinoStar, A-Level, H2, Eclat, or Henderson.** This is a fabricated Tavily answer — flag and ignore. The actual top hits are Instagram reels and the UFS Alzheimer's story, all unrelated to CelVivo.
- **Hermes Agent MiniMax M3 changelog 2026:** as noted above — first pull with non-noise Hermes/M3 evidence (configuration.md, api-server.md, MyClaw.ai, Instagram reel). Promotes the existing rows instead of spawning new ones.
- **OpenWiki connectors Tavily RAGFlow 2026:** recall still broken. Returns Roche ADLM 2026 (0.043), Nature chemical-reaction pathway algorithm (0.029), SmartBall X water infrastructure (0.025), exposure-management AI-attack cybersecurity (0.023), HID workforce unit transfer (0.019), **GEN "Downstream Purification Platform Breaks Complex Vector Bottleneck"** (0.017), RightShip maritime (0.016), insurance payment (0.016). Only the GEN vector-bottleneck item is mildly adjacent (cell-and-gene-therapy manufacturing); the rest is noise. Recommend dropping this lane from future Tavily runs.
### Synthesis result
- **Three new scope-aligned findings:**
1. **Cellink BIO X Gen 3 / BIO X6 customer evidence** — first vendor-anchored Cellink signal in any Tavily pull. Multi-source (Nuclear Mechano-Oncology LinkedIn install, CELLINK official LinkedIn BIO X6 at U. Miami, third-party market report, appellaser selection guide). Promoted to `/commitments.md` as `cellink-bio-x-gen3-customer-evidence`.
2. **China CGT regulatory landscape updates** — Merck–Bio-Techne $11.3B acquisition (June 2026); CARsgen satri-cel CAR-T approval for stomach cancer (June 2026); **gene-editing trial death + regulatory backlash** (Straits Times / LiveScience / SCMP coverage 2026-07-24 → 2026-07-29). Promoted to `/commitments.md` as `china-cgt-2026-july-developments` to track the gene-editing-death + China-biotech-backlash signal alongside the existing classification and Order No. 818 items.
3. **Hermes Agent v0.19 docs continue** — `configuration.md` iteration-budget behavior change (April 2026, documented 2026-07-26) + `api-server.md` new stop / approval endpoints (2026-07-27). Refreshes Last seen for `hermes-agent-v0-19-quicksilver`. MyClaw.ai confirms MiniMax M3 + M2.7 as the operational models for both OpenClaw and Hermes — refreshes Last seen for `MiniMax-m3`.
- **One application-domain cluster strengthens:** organ-on-chip (CN Bio + Ligand + Sequel Med Tech; NASA AVATAR + Emulate). Folds into the existing `class-organoid-3d-bioprinting` row without spawning a new theme.
- **Agent-memory-architecture cluster grows to 12+ distinct sources.** Hackernoon/Moorcheh.ai "Agent Memory Has a Lock-In Problem" is the strongest single OpenWiki-aligning source yet. Refreshes Last seen for `agent-memory-architecture`.
- **Tavily answer-text mis-attribution continues** on Q2 3Brain (5th pull). This is now a Tavily-side quality issue worth flagging in connector notes.
- **New Tavily hallucination pattern on Q6:** the Tavily answer text invented a specific claim about CelVivo ClinoStar being installed in "new A-Level (H2) science labs, such as the one opening in Eclat @ Henderson in August 2026." No underlying URL supports this. Treat Tavily answer text on the installed-base query as fabrication and ignore.
- **No 3Brain / CellShot-TriArm / OpenWiki-RAGFlow direct evidence** in this pull.
## Source coverage (cumulative)
- Pull 1: fetched 2026-07-26T17:39:11Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T17-38-33-286Z/web-search-results.json`
- Pull 2: fetched 2026-07-26T18:07:27Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-07-14-335Z/web-search-results.json`
- Pull 3: fetched 2026-07-26T18:16:21Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-16-06-804Z/web-search-results.json`
- Pull 4: fetched 2026-07-27T18:04:46Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-27T18-04-01-259Z/web-search-results.json`
- Pull 5: fetched 2026-07-28T18:04:26Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-28T18-03-43-560Z/web-search-results.json`
- Pull 6: fetched 2026-07-29T18:03:26Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-29T18-02-29-119Z/web-search-results.json`
- Queries: pulls 1, 2, 4, 5, 6 = 10 queries each; pull 3 = 6 queries (vendor-anchored only)
- Instance: `web-search-1`
themes.md
+4 -4
View File
@@ -6,13 +6,13 @@ Index kept narrow by design: only themes that map to Robin's actual work (life-s
| Topic key | Theme / Signal | First seen | Last seen | Confidence | Sources | Evidence count | Status | Evidence | | Topic key | Theme / Signal | First seen | Last seen | Confidence | Sources | Evidence count | Status | Evidence |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| `class-organoid-3d-bioprinting` | Recurring organoid, 3D bioprinting, and 3D-cell-culture automation coverage; this window adds a 2026-07-28 HN drug-discovery essay (owlposting "Why haven't organoids solved all of drug discovery?", 9 pts), a 2026-07-27 Oxford Academic review on 3D-bioprinted organoids, a 2026-07-22 Sage review on bioprinting-enabled organoids, a 2026-07-27 Pluristyx iPSC + aerospace clinical-grade hepatocyte manufacturing partnership, and the first vendor-anchored CelVivo ClinoReactor co-marketing signal (TheWell Bioscience xeno-free workflow pages) on top of the prior Nature / HN evidence; still mostly application-domain plus one vendor-channel signal | 2026-07-16 | 2026-07-28 | source-backed | hackernews, web-search | 18+ | active | [HN: 49083799 drug-discovery essay 2026-07-28](/sources/hackernews.md#class-organoid-3d-bioprinting-refreshed-this-run); [HN cluster](/sources/hackernews.md#class-organoid-3d-bioprinting-refreshed-this-run); [Tavily: 3D bioprinted organoid reviews + Pluristyx + CelVivo+TheWell 2026-07-27](/sources/web-search.md#2026-07-27-1804-pull) | | `class-organoid-3d-bioprinting` | Recurring organoid, 3D bioprinting, and 3D-cell-culture automation coverage; this window adds a 2026-07-28 HN drug-discovery essay (owlposting "Why haven't organoids solved all of drug discovery?", 9 pts), a 2026-07-27 Oxford Academic review on 3D-bioprinted organoids, a 2026-07-22 Sage review on bioprinting-enabled organoids, a 2026-07-27 Pluristyx iPSC + aerospace clinical-grade hepatocyte manufacturing partnership, the first vendor-anchored CelVivo ClinoReactor co-marketing signal (TheWell Bioscience xeno-free workflow pages), and the first vendor-anchored Cellink BIO X Gen 3 / BIO X6 signal (Nuclear Mechano-Oncology install + CELLINK LinkedIn U. Miami reference + third-party market report) plus GEN "Large Bioprinted Tissues Get a Precision Boost" (2026-07-29) and MDPI Cells "Rapid Volumetric Bioprinting Coupled with Dynamic Perfusion Enhances Human Hepatic Organoid Toxicity Testing" (2026-07-27) on top of the prior Nature / HN evidence; still mostly application-domain plus two vendor-channel signals | 2026-07-16 | 2026-07-29 | source-backed | hackernews, web-search | 20+ | active | [HN: 49083799 drug-discovery essay 2026-07-28](/sources/hackernews.md#class-organoid-3d-bioprinting-refreshed-this-run); [Tavily: 3D bioprinted organoid reviews + Pluristyx + CelVivo+TheWell 2026-07-27](/sources/web-search.md#2026-07-27-1804-pull); [Tavily: Cellink BIO X Gen 3 / BIO X6 + CN Bio / NASA AVATAR OOC + GEN bioprinting 2026-07-29](/sources/web-search.md#2026-07-29-1803-pull) |
| `china-cde-cell-gene-therapy-rules-2026` | China CDE (under NMPA) published technical guidelines defining scope & classification of cell and gene therapy drugs; standardizes CMC planning for Chinese pharma/CDMO/biotech customers | 2026-07-24 | 2026-07-24 | source-backed | web-search | 1 | watchlist | [Tavily: cisema.com 2026-07-24](/sources/web-search.md#china-cde-cell-gene-therapy-classification-source-backed) | | `china-cde-cell-gene-therapy-rules-2026` | China CDE (under NMPA) published technical guidelines defining scope & classification of cell and gene therapy drugs; standardizes CMC planning for Chinese pharma/CDMO/biotech customers | 2026-07-24 | 2026-07-24 | source-backed | web-search | 1 | watchlist | [Tavily: cisema.com 2026-07-24](/sources/web-search.md#china-cde-cell-gene-therapy-classification-source-backed) |
| `china-order-no-818-clinical-translation` | China's Order No. 818 (effective 2026-05-01) creates an accelerated pathway for advanced biomedical technologies — including cell therapy and 3D bioprinting — towards regulated clinical translation at qualified hospitals after demonstrating safety and preliminary efficacy; the clinical-translation counterpart to the CDE classification item and directly relevant to Robin's Chinese pharma R&D / CDMO / biotech customer base | 2026-07-28 | 2026-07-28 | source-backed | web-search | 1 (+ Tavily synthesis) | watchlist | [Tavily: BetaLife LinkedIn 2026-07 + Roots Analysis re-mention 2026-07-28](/sources/web-search.md#china-order-no-818--accelerated-clinical-translation-pathway--source-backed) | | `china-order-no-818-clinical-translation` | China's Order No. 818 (effective 2026-05-01) creates an accelerated pathway for advanced biomedical technologies — including cell therapy and 3D bioprinting — towards regulated clinical translation at qualified hospitals after demonstrating safety and preliminary efficacy; the clinical-translation counterpart to the CDE classification item and directly relevant to Robin's Chinese pharma R&D / CDMO / biotech customer base | 2026-07-28 | 2026-07-28 | source-backed | web-search | 1 (+ Tavily synthesis) | watchlist | [Tavily: BetaLife LinkedIn 2026-07 + Roots Analysis re-mention 2026-07-28](/sources/web-search.md#china-order-no-818--accelerated-clinical-translation-pathway--source-backed) |
| `MiniMax-m3` | MiniMax-M3 (1M context multimodal) HuggingFace model card + Twitter launch; the daily-driver inference provider behind every OpenWiki run and most of Robin's agent work; haimaker.ai July 2026 third-party eval ranks models for Hermes Agent usage | 2026-07-16 | 2026-07-23 | watchlist | hackernews, web-search | 3 | watchlist | [HN: M3 model cluster (huggingface + twitter)](/sources/hackernews.md#MiniMax-m3-watchlist); [Tavily: Hermes Agent best-models eval](/sources/web-search.md#hermes-agent-best-models-eval-source-backed-workflow-tooling-low-priority) | | `MiniMax-m3` | MiniMax-M3 (1M context multimodal) HuggingFace model card + Twitter launch; the daily-driver inference provider behind every OpenWiki run and most of Robin's agent work; haimaker.ai July 2026 third-party eval ranks models for Hermes Agent usage; MyClaw.ai 2026-07-29 confirms M3 + M2.7 are the operational models for both OpenClaw and Hermes, with M3 supporting multimodal (image, video, music, speech, web search) | 2026-07-16 | 2026-07-29 | watchlist | hackernews, web-search | 5 | watchlist | [HN: M3 model cluster (huggingface + twitter)](/sources/hackernews.md#MiniMax-m3-watchlist); [Tavily: Hermes Agent best-models eval](/sources/web-search.md#hermes-agent-best-models-eval-source-backed-workflow-tooling-low-priority); [Tavily: MyClaw OpenClaw vs MiniMax Agent 2026-07-29](/sources/web-search.md#2026-07-29-1803-pull) |
| `hermes-agent-v0-19-quicksilver` | Hermes Agent v0.19 "Quicksilver" release (2026-07-25): first-token delay 4.3s → 0.9s, profile routing, live subagent, delivery ledger, 1Password/Bitwarden integration; relevant to Robin's daily-driver stack; MCP 2026-07-28 revision finalization (not backward-compatible) is a related protocol-layer signal | 2026-07-25 | 2026-07-25 | source-backed | web-search | 4 | active | [Tavily: Hermes v0.19 Quicksilver + MCP revision 2026-07-27](/sources/web-search.md#hermes-agent-v019-quicksilver-release--source-backed-workflow-tooling-low-priority) | | `hermes-agent-v0-19-quicksilver` | Hermes Agent v0.19 "Quicksilver" release (2026-07-25): first-token delay 4.3s → 0.9s, profile routing, live subagent, delivery ledger, 1Password/Bitwarden integration; relevant to Robin's daily-driver stack; MCP 2026-07-28 revision finalization (not backward-compatible) is a related protocol-layer signal; `configuration.md` (2026-07-26) documents the iteration-budget behavior change (April 2026: removed premature 70%/90% warnings, now single wrap-up at 500/500 with grace call) and `features/api-server.md` (2026-07-27) documents new `/v1/runs/{run_id}/stop` + `/approval` endpoints with MiniMax-M3 as the documented default model | 2026-07-25 | 2026-07-29 | source-backed | web-search | 6 | active | [Tavily: Hermes v0.19 Quicksilver + MCP revision 2026-07-27](/sources/web-search.md#hermes-agent-v019-quicksilver-release--source-backed-workflow-tooling-low-priority); [Tavily: hermes-agent configuration.md + api-server.md + MyClaw 2026-07-29](/sources/web-search.md#2026-07-29-1803-pull) |
| `openwiki-brand` | `langchain-ai/openwiki` (96 pts) — same product family as Robin's OpenWiki; high-engagement on HN | 2026-07-16 | 2026-07-16 | source-backed | hackernews | 1 (+ 2 adjacent wrappers) | watchlist | [HN: openwiki cluster](/sources/hackernews.md#openwiki-brand-signal) | | `openwiki-brand` | `langchain-ai/openwiki` (96 pts) — same product family as Robin's OpenWiki; high-engagement on HN | 2026-07-16 | 2026-07-16 | source-backed | hackernews | 1 (+ 2 adjacent wrappers) | watchlist | [HN: openwiki cluster](/sources/hackernews.md#openwiki-brand-signal) |
| `agent-memory-architecture` | Shared agent-memory architecture using Karpathy's LLM Wiki + Google's Open Knowledge Format (OKF) + MCP — let "every Local AI share ONE permanent memory"; this 2026-07-28 Tavily pull surfaces five corroborated sources (YouTube Kai, Taskade, SamurAIGPT GitHub, LinkedIn Bressler, Reddit r/ClaudeAI) on top of the three prior HN Show HN items, making this multi-source corroborated and directly adjacent to OpenWiki's role | 2026-07-26 | 2026-07-28 | source-backed | hackernews, web-search | 8+ | active | [HN: 49059959, 49059889, 49060215](/sources/hackernews.md#agent-memory-architecture-watchlist--new); [Tavily: LLM Wiki + OKF cluster 2026-07-28](/sources/web-search.md#llm-wiki--okf--shared-agent-memory-cluster--source-backed-workflow-tooling-low-priority) | | `agent-memory-architecture` | Shared agent-memory architecture using Karpathy's LLM Wiki + Google's Open Knowledge Format (OKF) + MCP — let "every Local AI share ONE permanent memory"; this 2026-07-29 Tavily pull adds four more corroborated sources (Hackernoon Moorcheh.ai "Agent Memory Has a Lock-In Problem. Open Formats Are How We Fix It." with diffability / reviewability / auditability framing; Towards Data Science "Usage-Reinforced Decay Engine for AI Agent Memory" using Ebbinghaus forgetting curve; The Register / MinIO AIStor Memory for long-running multi-step workflows; HPCwire Exabase M-1 BEAM benchmark numbers 76.9% / 75.0% / 68.0% at 100K/1M/10M tokens) on top of the prior HN + Tavily sources; the Hackernoon piece is the strongest OpenWiki-aligning source yet | 2026-07-26 | 2026-07-29 | source-backed | hackernews, web-search | 12+ | active | [HN: 49059959, 49059889, 49060215](/sources/hackernews.md#agent-memory-architecture-watchlist--new); [Tavily: LLM Wiki + OKF cluster 2026-07-28](/sources/web-search.md#llm-wiki--okf--shared-agent-memory-cluster--source-backed-workflow-tooling-low-priority); [Tavily: Moorcheh.ai + TDS + MinIO + Exabase cluster 2026-07-29](/sources/web-search.md#2026-07-29-1803-pull) |
## Notes ## Notes